NCT06121401 2025-09-17
IOLANTHE
Mario Negri Institute for Pharmacological Research
Phase 4 Active not recruiting
Clinical Trials
13 trialsNCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT02022917 2021-01-27
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Chang Gung Memorial Hospital
Phase 2 Completed
NCT04556071 2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT03220932 2019-11-01
HIPOVA-01
Hospices Civils de Lyon
Phase 3 Unknown
NCT01832415 2016-03-17
ENCOURAGE
ARCAGY/ GINECO GROUP
Completed
NCT00504257 2014-02-06
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01202890 2014-01-08
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00407563 2012-04-05
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed